查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物製药製程分析技术的全球市场：市场规模 - 按类型、按产品类型、按模式、按应用、按地区 - 预测到 2029 年
市场调查报告书
商品编码
1482051

生物製药製程分析技术的全球市场：市场规模 - 按类型、按产品类型、按模式、按应用、按地区 - 预测到 2029 年

Biopharmaceutical Process Analytical Technology Market Size by Technology (LC, GC, MS, qPCR, NGS, NMR, Raman, IR Spectroscopy), Product (Analyzer, Sensor, Software), Application (Vaccine, Biologics, CGT), and End User - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 248 Pages | 订单完成后即时交付

价格
简介目录

全球生物製药製程分析技术市场规模预计将从 2024 年的 12 亿美元增至 2029 年的 26 亿美元，预测期内复合年增长率为 16.0%。

在生物製药研发活动活性化以及提高製程效率的技术进步的推动下，市场正在不断成长。然而，缺乏熟练的人力和实施过程分析技术（PAT）的高成本等障碍正在阻碍市场的成长。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
考虑单位 金额（十亿美元）
部分 按类型、产品类型、模式、应用、地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲

依类型划分，全球生物製药流程分析技术市场分为液相层析法、气相层析法、质谱法、即时PCR/QPCR、NGS、核磁共振光谱法、拉曼光谱法、红外线光谱法、粒子计数成像法、以及微分光谱法。从技术来看，液相层析法/HPLC将在2023年占据主要市场占有率。越来越多地采用液相层析法/HPLC技术进行生物製药品质评估，是支持该领域快速扩张的关键因素。

提供生物製药过程分析技术（PAT）服务以加强QbD框架的实施。这些服务包括各种软体解决方案，包括 PAT 实施咨询、软体开发、法规遵循和流程管理。由于在生物製药製造中创建 PAT 模型和实施 PAT 策略至关重要的服务的需求不断增加，预计软体产业将显着成长。

生物製药製程分析技术市场依应用大致分为疫苗、细胞/基因治疗、生物相似药/生物製剂、荷尔蒙疗法和其他应用。 2023年，疫苗产业将占据最大的市场份额。药物开发和安全方面的严格监管是该行业扩张的主要驱动力，提高了生物製药製造的效率和效果。此外，为满足不断增长的药品需求而加强生物製药研究力度和增加产量也对该行业的成长做出了重大贡献。

本报告研究了全球生物製药流程分析技术市场，并按类型、产品类型、模式、应用、区域和参与市场的公司概况总结了趋势。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 监管分析
  • 价值链分析
  • 供应链分析
  • 生态系分析
  • 投资金筹措场景
  • 价格分析
  • 贸易分析
  • 专利分析
  • 波特五力分析
  • 重大会议及活动
  • 案例研究分析
  • 技术分析
  • 影响客户业务的趋势/干扰
  • 主要相关人员和采购标准
  • 未满足的需求和主要问题

第六章生物製药流程分析技术市场（按类型）

  • 介绍
  • 液相层析法/HPLC
  • 气相层析法
  • 质谱
  • 即时PCR/QPCR
  • 次世代定序
  • 核磁共振波谱
  • 拉曼光谱
  • 红外线光谱
  • 粒子计数器和成像
  • 光散射分析
  • 其他的

第七章生物製药流程分析技术市场，依产品类型

  • 介绍
  • 分析仪
  • 感测器和探头
  • 采样器
  • 软体

第八章生物製药流程分析技术市场（按模式）

  • 介绍
  • 在线测量
  • 离线测量
  • 在线测量
  • 在线测量

第九章生物製药製程分析技术市场（按应用）

  • 介绍
  • 疫苗
  • 细胞/基因治疗
  • 生物相似药和生物製药
  • 荷尔蒙疗法
  • 其他的

第10章生物製药製程分析技术市场（按地区）

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第十一章竞争格局

  • 概述
  • 主要参与企业的策略/秘密
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要参与企业
  • 公司评估矩阵：Start-Ups/中小企业
  • 公司评价及财务指标
  • 品牌/产品比较
  • 竞争场景

第十二章 公司简介

  • 主要参与企业
    • WATERS CORPORATION
    • DANAHER CORPORATION
    • THERMO FISHER SCIENTIFIC INC.
    • AGILENT TECHNOLOGIES, INC.
    • SHIMADZU CORPORATION
    • PERKINELMER, INC.
    • BRUKER CORPORATION
    • METTLER-TOLEDO INTERNATIONAL INC.
    • CARL ZEISS AG（ZEISS GROUP）
    • EMERSON ELECTRIC CO.
    • ABB
    • SARTORIUS AG
    • PROCESS INSIGHTS, INC.
    • MERCK KGAA
    • VERUM ANALYTICS, LLC
  • 其他公司
    • HAMILTON COMPANY
    • ENDRESS+HAUSER GROUP SERVICES AG
    • VIAVI SOLUTIONS INC.
    • METROHM AG
    • CONTROL DEVELOPMENT, INC.
    • NECI
    • SCHMIDT+HAENSCH
    • SENSUM DOO
    • AMETEK, INC.
    • SENTRONIC GMBH

第十三章附录

简介目录
Product Code: AST 9019

The global biopharmaceutical process analytical technology market is projected to reach USD 2.6 billion by 2029 from USD 1.2 billion in 2024, at a CAGR of 16.0% during the forecast period of 2024 to 2029. The market is on an upward trajectory fueled by a rise in biopharmaceutical research and development activities, coupled with technological advancements improving process efficiency. However, obstacles such as a shortage of skilled personnel and the high costs of implementing process analytical technology (PAT) are hindering the market's growth.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsType, Product Type, Mode, Application, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The liquid chromatography/HPLC segment to hold the largest share of the market in 2023."

Based on the type, the global biopharmaceutical process analytical technology market has been classified into five major segments-liquid chromatography, gas chromatography, mass spectrometry, real-time PCR/QPCR, NGS, NMR spectroscopy, Raman spectroscopy, infrared spectroscopy, particle counters and imaging, differential light scattering, and other techniques. By technology, liquid chromatography/HPLC to hold major market share in 2023. The growing adoption of liquid chromatography/HPLC technologies for assessing the quality of biopharmaceutical drugs is a key driver behind the sector's rapid expansion.

"The software segment is projected to register the highest CAGR during the forecast period."

Biopharmaceutical process analytical technology (PAT) services are provided to enhance the implementation of the Quality by Design (QbD) framework. These services encompass various software solutions, including consultation on PAT adoption, software development, regulatory compliance, and process management. The software sector is expected to witness significant growth, driven by increasing demand for services essential in creating PAT models and executing PAT strategies in biopharmaceutical manufacturing.

"In terms of application, vaccines segment held the largest share of the market in 2023."

Based on application, the biopharmaceutical process analytical technology market is broadly segmented into vaccines, cell and gene therapy, biosimilars & biologics, hormonal therapy, and other applications. The vaccines segment commanded the largest share of the market in 2023. Strict regulations in drug development and safety are the main drivers behind the expansion of this sector, bolstering the efficiency and effectiveness of biopharmaceutical manufacturing. Furthermore, heightened efforts in biopharmaceutical research and the expansion of production to address rising medicine demands are substantial contributors to this growth.

"The market in the APAC region is expected to witness the highest growth during the forecast period."

China, India, and Japan are the key markets in the Asia Pacific. The growth of the Asia Pacific market is being driven by strategic expansions undertaken by major market players in emerging Asian nations, the flourishing Contract Research and Manufacturing Services (CRAMs) industry in India, Korea, Singapore, and China, the substantial biopharmaceutical industry presence in Singapore, as well as the organization of conferences, exhibitions, and meetings focusing on analytical instruments.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1 30%, Tier 2-42%, and Tier 3- 28%
  • By Designation: C-level-14%, D Level-10%, and Others-76%
  • By Region: North America-40%, Europe-30%, Asia Pacific-22%, Latin America-6%, and the Middle East & Africa-2%

The prominent players in the biopharmaceutical process analytical technology market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Shimadzu Corporation (Japan), Waters Corporation (US), Bruker Corporation (US), Emerson Electric Co. (US), ABB Ltd. (Switzerland), PerkinElmer, Inc. (US), Mettler-Toledo International Inc. (US), and Carl Zeiss AG (Germany), among others.

Research Coverage

This report studies the biopharmaceutical process analytical technology market based on type, product type, mode, application, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions)

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the biopharmaceutical process analytical technology market
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the biopharmaceutical process analytical technology market
  • Market Development: Comprehensive information on lucrative emerging regions
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the biopharmaceutical process analytical technology market
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 YEARS CONSIDERED
    • 1.3.3 CURRENCY CONSIDERED
  • 1.4 RESEARCH LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primaries
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 5 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
      • 2.2.1.2 Approach 2: Customer-based market estimation
    • FIGURE 6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projection
    • FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
  • 2.3 DATA VALIDATION APPROACH
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ASSESSMENT
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 GROWTH RATE ASSUMPTIONS
  • 2.7 RESEARCH LIMITATIONS
  • 2.8 RISK ASSESSMENT
  • 2.9 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
    • FIGURE 11 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024 VS. 2029
    • FIGURE 12 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET OVERVIEW
    • FIGURE 13 GROWING R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
  • 4.2 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE
    • FIGURE 14 ONLINE MEASUREMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.3 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION AND APPLICATION
    • FIGURE 15 NORTH AMERICA TO HOLD LARGEST SHARE OF ALL APPLICATION SEGMENTS IN 2024
  • 4.4 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising R&D investments by pharma companies and governments in emerging markets
    • FIGURE 18 PHARMACEUTICAL R&D EXPENDITURE: ANNUAL GROWTH RATE (%)
      • 5.2.1.2 Growing incidence of infectious diseases and essential contribution of PAT in vaccine development
      • 5.2.1.3 Requirement for improved efficiency in manufacturing processes driving enhancements in quality
      • 5.2.1.4 Advancements in analytical device technology
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of process analytical technology deployment
      • 5.2.2.2 Governmental regulations pertaining to safety of drugs
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing interest in PAT in emerging markets
      • 5.2.3.2 Increasing utilization of analytical instruments in biopharmaceutical processes
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Lack of skilled professionals
  • 5.3 REGULATORY ANALYSIS
    • 5.3.1 REGULATORY LANDSCAPE
    • TABLE 1 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PROCESS ANALYTICAL TECHNOLOGY, BY COUNTRY/REGION
    • 5.3.2 KEY REGULATORY BODIES & GOVERNMENT AGENCIES
    • TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.3.3 KEY REGULATORY GUIDELINES
      • 5.3.3.1 US
      • 5.3.3.2 Europe
      • 5.3.3.3 Asia Pacific
      • 5.3.3.4 Rest of the World
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
    • 5.5.1 PROMINENT COMPANIES
    • 5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
    • 5.5.3 END USERS
    • FIGURE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 21 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
    • TABLE 7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ROLE IN ECOSYSTEM
  • 5.7 INVESTMENT & FUNDING SCENARIO
    • FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2018-2022
    • FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018-2022 (USD MILLION)
  • 5.8 PRICING ANALYSIS
    • FIGURE 24 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY TYPE (USD THOUSAND)
    • FIGURE 25 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY REGION (USD THOUSAND)
    • TABLE 8 AVERAGE SELLING PRICE OF PROCESS ANALYTICAL TECHNOLOGIES, BY REGION, 2021-2023 (USD THOUSAND)
  • 5.9 TRADE ANALYSIS
    • 5.9.1 IMPORT DATA
    • TABLE 9 IMPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019-2023 (USD THOUSAND)
    • TABLE 10 IMPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019-2023 (USD THOUSAND)
    • 5.9.2 EXPORT DATA
    • TABLE 11 EXPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019-2023 (USD THOUSAND)
    • TABLE 12 EXPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019-2023 (USD THOUSAND)
  • 5.10 PATENT ANALYSIS
    • 5.10.1 PATENT DETAILS FOR BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (JANUARY 2013-DECEMBER 2023)
  • 5.11 PORTER'S FIVE FORCE ANALYSIS
    • TABLE 13 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY CONFERENCES & EVENTS
    • TABLE 14 LIST OF MAJOR CONFERENCES & EVENTS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET IN JANUARY 2024-DECEMBER 2024
  • 5.13 CASE STUDY ANALYSIS
    • 5.13.1 NAVIGATING DIGITAL TRANSFORMATION: INTEGRATING ADVANCED TECHNOLOGIES FOR PAT IN BIOPHARMACEUTICAL MANUFACTURING.
      • 5.13.1.1 Case 1: Advancements in process analytical technology
  • 5.14 TECHNOLOGY ANALYSIS
    • 5.14.1 KEY TECHNOLOGIES
      • 5.14.1.1 Mass spectrometry (MS)
      • 5.14.1.2 Liquid chromatography/HPLC
    • 5.14.2 COMPLEMENTARY TECHNOLOGIES
      • 5.14.2.1 Advanced sensor technologies
    • 5.14.3 ADJACENT TECHNOLOGIES
      • 5.14.3.1 Bioprocess monitoring and control systems
  • 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 26 REVENUE SHIFT IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET
  • 5.16 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
    • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
    • 5.16.2 BUYING CRITERIA
    • FIGURE 28 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
    • TABLE 16 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
  • 5.17 UNMET NEEDS AND KEY PAIN POINTS
    • TABLE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: CURRENT UNMET NEEDS

6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 18 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET VOLUME, BY TYPE, 2022-2029 (MILLION UNITS)
    • TABLE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 6.2 LIQUID CHROMATOGRAPHY/HPLC
    • 6.2.1 EARLY AND EFFICIENT SAMPLE ANALYSIS ASSOCIATED WITH LC TO DRIVE MARKET GROWTH
    • TABLE 21 DIFFERENTIATION OF LIQUID CHROMATOGRAPHY SYSTEMS
    • TABLE 22 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 23 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 24 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.3 GAS CHROMATOGRAPHY
    • 6.3.1 GROWING ADOPTION OF COMPACT GC SYSTEMS IN MANUFACTURING FACILITIES TO BOLSTER GROWTH
    • TABLE 25 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 26 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 27 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.4 MASS SPECTROMETRY
    • 6.4.1 GROWING NEED FOR DUAL-MASS ANALYZERS TO PROPEL GROWTH
    • TABLE 28 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 29 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 30 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.5 REAL-TIME PCR/QPCR
    • 6.5.1 EXPANSION OF PCR INSTRUMENTATION TO FAVOR MARKET GROWTH
    • TABLE 31 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 32 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.6 NEXT-GENERATION SEQUENCING
    • 6.6.1 INCREASING INVESTMENTS IN NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGIES TO DRIVE MARKET EXPANSION
    • TABLE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.7 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
    • 6.7.1 ADVANCING BIOPHARMACEUTICAL QUALITY AND EFFICIENCY THROUGH NMR SPECTROSCOPY TO BOOST MARKET
    • TABLE 37 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 38 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 39 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.8 RAMAN SPECTROSCOPY
    • 6.8.1 EXPANDING ROLE OF RAMAN SPECTROSCOPY IN PROCESS MONITORING AND QUALITY CONTROL TO BOOST MARKET
    • TABLE 40 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 41 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 42 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.9 INFRARED SPECTROSCOPY
    • 6.9.1 INCREASING UTILIZATION OF MINIATURIZED GC SYSTEMS IN PRODUCTION PLANTS TO SUPPORT GROWTH
    • TABLE 43 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 44 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 45 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.10 PARTICLE COUNTERS & IMAGING
    • 6.10.1 INCREASING DEMAND FOR HIGH-QUALITY MEDICATIONS WITH REDUCED SIDE EFFECTS TO FACILITATE MARKET ACCEPTANCE
    • TABLE 46 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 47 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 48 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.11 DIFFERENTIAL LIGHT SCATTERING
    • 6.11.1 CONTROLLED MANUFACTURING OF PHARMACEUTICALS WITH FEWER SIDE EFFECTS TO BOOST ADOPTION
    • TABLE 49 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 50 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 51 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY APPLICATION, 2022-2029 (USD MILLION)
  • 6.12 OTHER TECHNIQUES
    • TABLE 52 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY REGION, 2022-2029 (USD MILLION)
    • TABLE 53 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 54 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY APPLICATION, 2022-2029 (USD MILLION)

7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE

  • 7.1 INTRODUCTION
    • TABLE 55 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
  • 7.2 ANALYZERS
    • 7.2.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
    • TABLE 56 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ANALYZERS, BY REGION, 2022-2029 (USD MILLION)
  • 7.3 SENSORS & PROBES
    • 7.3.1 QUICK TURNAROUND TIMES AND AUTOMATED PROCESSES TO FACILITATE MARKET ADOPTION
    • TABLE 57 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SENSORS & PROBES, BY REGION, 2022-2029 (USD MILLION)
  • 7.4 SAMPLERS
    • 7.4.1 HIGH LEVEL OF ACCURACY AND REPRODUCIBILITY TO DRIVE MARKET GROWTH
    • TABLE 58 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SAMPLERS, BY REGION, 2022-2029 (USD MILLION)
  • 7.5 SOFTWARE
    • 7.5.1 GROWING ADOPTION OF PAT FRAMEWORKS WITHIN PHARMACEUTICAL COMPANIES TO BOLSTER ADOPTION
    • TABLE 59 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SOFTWARE, BY REGION, 2022-2029 (USD MILLION)

8 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE

  • 8.1 INTRODUCTION
    • TABLE 60 COMPARISON BETWEEN MEASUREMENT METHODS IN PAT
    • TABLE 61 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022-2029 (USD MILLION)
  • 8.2 ONLINE MEASUREMENT
    • 8.2.1 IMPROVED PROCESS EFFICIENCY AND REDUCED PRODUCTION COSTS TO BOOST ADOPTION
    • TABLE 62 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ONLINE MEASUREMENT, BY REGION, 2022-2029 (USD MILLION)
  • 8.3 OFFLINE MEASUREMENT
    • 8.3.1 HIGH FLEXIBILITY OF OFFLINE ANALYSIS TO DRIVE GROWTH
    • TABLE 63 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OFFLINE MEASUREMENT, BY REGION, 2022-2029 (USD MILLION)
  • 8.4 AT-LINE MEASUREMENT
    • 8.4.1 GROWING USE OF AT-LINE MEASUREMENT TO BOOST MARKET GROWTH
    • TABLE 64 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR AT-LINE MEASUREMENT, BY REGION, 2022-2029 (USD MILLION)
  • 8.5 IN-LINE MEASUREMENT
    • 8.5.1 FAST TURNAROUND TIME TO BOOST SEGMENTAL GROWTH
    • TABLE 65 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR IN-LINE MEASUREMENT, BY REGION, 2022-2029 (USD MILLION)

9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 66 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • 9.2 VACCINES
    • 9.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH FOR VACCINES
    • TABLE 67 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR VACCINES, BY REGION, 2022-2029 (USD MILLION)
  • 9.3 CELL & GENE THERAPY
    • 9.3.1 GROWING DEMAND FOR STEM CELL AND CAR-T THERAPIES TO BOOST MARKET GROWTH
    • TABLE 68 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR CELL & GENE THERAPY, BY REGION, 2022-2029 (USD MILLION)
  • 9.4 BIOSIMILARS & BIOLOGICS
    • 9.4.1 HIGH LEVELS OF ACCURACY AND REPRODUCIBILITY TO PROPEL DEMAND FOR BIOSIMILARS & BIOLOGICS
    • TABLE 69 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR BIOSIMILARS & BIOLOGICS, BY REGION, 2022-2029 (USD MILLION)
  • 9.5 HORMONAL THERAPY
    • 9.5.1 IMPROVING CANCER TREATMENT WITH ADVANCED HORMONAL THERAPY TO FAVOR MARKET GROWTH
    • FIGURE 29 GLOBAL CANCER CASES, 202O VS. 2022
    • TABLE 70 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR HORMONAL THERAPY, BY REGION, 2022-2029 (USD MILLION)
  • 9.6 OTHER APPLICATIONS
    • TABLE 71 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)

10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 72 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • TABLE 73 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 74 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 75 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 76 NORTH AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
    • TABLE 77 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • 10.2.2 US
      • 10.2.2.1 Stringent regulations and dominance of pharma and biopharma firms to propel market growth
    • TABLE 78 US: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Widespread occurrence of cancer and promising funding landscape to bolster market growth
    • TABLE 79 CANADA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 10.3 EUROPE
    • 10.3.1 EUROPE: RECESSION IMPACT
    • TABLE 80 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 81 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 82 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 83 EUROPE: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
    • TABLE 84 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • 10.3.2 GERMANY
      • 10.3.2.1 Growing adoption of biopharmaceutical process analytical technology (PAT) to propel market
    • TABLE 85 GERMANY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Infrastructure development and increasing life science R&D investment to propel growth
    • TABLE 86 FRANCE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.4 UK
      • 10.3.4.1 Government initiatives to boost market expansion
    • TABLE 87 UK: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Conducive funding environment in Italy to boost market
    • TABLE 88 ITALY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Growing focus on cancer screening and digital health initiatives to boost market
    • TABLE 89 SPAIN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 90 REST OF EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 31 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • TABLE 91 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 94 ASIA PACIFIC: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Advanced infrastructure to support market growth in Japan
    • TABLE 96 JAPAN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Growing demand for PAT to boost market
    • TABLE 97 CHINA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Growing biopharmaceutical industry to drive market growth
    • TABLE 98 INDIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 Government investments to propel market growth
    • TABLE 99 AUSTRALIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Extensive insurance coverage to boost market growth
    • TABLE 100 SOUTH KOREA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.4.7 REST OF ASIA PACIFIC
    • TABLE 101 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 LATIN AMERICA: RECESSION IMPACT
    • TABLE 102 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
    • TABLE 103 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 104 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 105 LATIN AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
    • TABLE 106 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
    • 10.5.2 BRAZIL
      • 10.5.2.1 Expansion within biopharmaceutical sector to contribute to market growth
    • TABLE 107 BRAZIL: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.5.3 MEXICO
      • 10.5.3.1 Growing exports of biopharmaceuticals to drive market in Mexico
    • TABLE 108 MEXICO: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • 10.5.4 REST OF LATIN AMERICA
    • TABLE 109 REST OF LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
    • TABLE 110 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022-2029 (USD MILLION)
    • TABLE 111 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022-2029 (USD MILLION)
    • TABLE 112 MIDDLE EAST & AFRICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022-2029 (USD MILLION)
    • TABLE 113 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022-2029 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET
    • TABLE 114 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES
  • 11.3 REVENUE ANALYSIS
    • FIGURE 32 REVENUE ANALYSIS OF TOP THREE PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET (2019-2023)
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
    • TABLE 115 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS
    • FIGURE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY FOOTPRINT
    • TABLE 116 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT FOOTPRINT
    • TABLE 117 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: REGIONAL FOOTPRINT
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • FIGURE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
    • 11.6.5 COMPETITIVE BENCHMARKING
    • TABLE 118 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
    • TABLE 119 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
    • FIGURE 37 EV/EBITDA OF KEY VENDORS
    • FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • 11.8 BRAND/PRODUCT COMPARISON
    • FIGURE 39 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES
    • TABLE 120 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT LAUNCHES, JANUARY 2020-MARCH 2024
    • 11.9.2 DEALS
    • TABLE 121 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEALS, JANUARY 2020-MARCH 2024
    • 11.9.3 EXPANSIONS
    • TABLE 122 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: EXPANSIONS, JANUARY 2020-APRIL 2024

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 WATERS CORPORATION
    • TABLE 123 WATERS CORPORATION: COMPANY OVERVIEW
    • FIGURE 40 WATERS CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 124 WATERS CORPORATION: PRODUCTS OFFERED
    • TABLE 125 WATERS CORPORATION: DEALS
    • 12.1.2 DANAHER CORPORATION
    • TABLE 126 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 127 DANAHER CORPORATION: PRODUCTS OFFERED
    • TABLE 128 DANAHER CORPORATION: DEALS
    • 12.1.3 THERMO FISHER SCIENTIFIC INC.
    • TABLE 129 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
    • FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
    • TABLE 130 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
    • TABLE 131 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES
    • TABLE 132 THERMO FISHER SCIENTIFIC INC.: DEALS
    • 12.1.4 AGILENT TECHNOLOGIES, INC.
    • TABLE 133 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
    • TABLE 134 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
    • TABLE 135 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES
    • TABLE 136 AGILENT TECHNOLOGIES, INC.: DEALS
    • 12.1.5 SHIMADZU CORPORATION
    • TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
    • FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022)
    • TABLE 138 SHIMADZU CORPORATION: PRODUCTS OFFERED
    • TABLE 139 SHIMADZU CORPORATION: PRODUCT LAUNCHES
    • TABLE 140 SHIMADZU CORPORATION: EXPANSIONS
    • 12.1.6 PERKINELMER, INC.
    • TABLE 141 PERKINELMER, INC.: COMPANY OVERVIEW
    • FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2022)
    • TABLE 142 PERKINELMER, INC.: PRODUCTS OFFERED
    • TABLE 143 PERKINELMER, INC.: PRODUCT LAUNCHES
    • 12.1.7 BRUKER CORPORATION
    • TABLE 144 BRUKER CORPORATION: COMPANY OVERVIEW
    • FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2023)
    • TABLE 145 BRUKER CORPORATION: PRODUCTS OFFERED
    • TABLE 146 BRUKER CORPORATION: PRODUCT LAUNCHES
    • TABLE 147 BRUKER CORPORATION: DEALS
    • 12.1.8 METTLER-TOLEDO INTERNATIONAL INC.
    • TABLE 148 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY OVERVIEW
    • FIGURE 47 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY SNAPSHOT (2023)
    • TABLE 149 METTLER-TOLEDO INTERNATIONAL INC.: PRODUCTS OFFERED
    • TABLE 150 METTLER-TOLEDO INTERNATIONAL INC.: DEALS
    • 12.1.9 CARL ZEISS AG (ZEISS GROUP)
    • TABLE 151 CARL ZEISS AG: COMPANY OVERVIEW
    • FIGURE 48 CARL ZEISS AG: COMPANY SNAPSHOT (2022)
    • TABLE 152 CARL ZEISS AG: PRODUCTS OFFERED
    • 12.1.10 EMERSON ELECTRIC CO.
    • TABLE 153 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
    • FIGURE 49 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
    • TABLE 154 EMERSON ELECTRIC CO.: PRODUCTS OFFERED
    • 12.1.11 ABB
    • TABLE 155 ABB: COMPANY OVERVIEW
    • FIGURE 50 ABB: COMPANY SNAPSHOT (2023)
    • TABLE 156 ABB: PRODUCTS OFFERED
    • TABLE 157 ABB: EXPANSIONS
    • 12.1.12 SARTORIUS AG
    • TABLE 158 SARTORIUS AG: COMPANY OVERVIEW
    • FIGURE 51 SARTORIUS AG: COMPANY SNAPSHOT (2023)
    • TABLE 159 SARTORIUS AG: PRODUCTS OFFERED
    • TABLE 160 SARTORIUS AG: DEALS
    • TABLE 161 SARTORIUS AG: EXPANSIONS
    • 12.1.13 PROCESS INSIGHTS, INC.
    • TABLE 162 PROCESS INSIGHTS, INC.: COMPANY OVERVIEW
    • TABLE 163 PROCESS INSIGHTS, INC.: PRODUCTS OFFERED
    • 12.1.14 MERCK KGAA
    • TABLE 164 MERCK KGAA: COMPANY OVERVIEW
    • FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
    • TABLE 165 MERCK KGAA: PRODUCTS OFFERED
    • TABLE 166 MERCK KGAA: DEALS
    • 12.1.15 VERUM ANALYTICS, LLC
    • TABLE 167 VERUM ANALYTICS, LLC: COMPANY OVERVIEW
    • TABLE 168 VERUM ANALYTICS, LLC: PRODUCTS OFFERED
  • 12.2 OTHER PLAYERS
    • 12.2.1 HAMILTON COMPANY
    • 12.2.2 ENDRESS+HAUSER GROUP SERVICES AG
    • 12.2.3 VIAVI SOLUTIONS INC.
    • 12.2.4 METROHM AG
    • 12.2.5 CONTROL DEVELOPMENT, INC.
    • 12.2.6 NECI
    • 12.2.7 SCHMIDT + HAENSCH
    • 12.2.8 SENSUM D.O.O.
    • 12.2.9 AMETEK, INC.
    • 12.2.10 SENTRONIC GMBH
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS